CRP assessment
PreclinicalBiologic
CRP assessment is one of 21 biologic programs targeting Heart Rate Variability. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Acute Respiratory Distress Syndrome
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Revia
TevaApproved
Decadron
AAspen Global Incorporated
Approved
Esbriet
LLegacy Health System
Approved
Foradil
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Duragesic
CCephalon
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Supportive Care
BeiGenePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Respiratory Distress Syndrome1 trial
Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress Syndrome
Terminated·—·N/A·NCT05330845·35 enrolled
Heart Rate Variability1 trial
Heart Rate Variability, Vagus Nerve and Cancer
Terminated·—·N/A·NCT04718610·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CRP assessment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details